BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS

生物反应调节剂作为艾滋病疗法

基本信息

  • 批准号:
    2296951
  • 负责人:
  • 金额:
    $ 26.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1987
  • 资助国家:
    美国
  • 起止时间:
    1987-09-01 至 1992-08-31
  • 项目状态:
    已结题

项目摘要

The objective of this contract is to facilitate the entry of biological response modifiers (BRMs) into clinical trials. This will be accomplished by examining the potential efficacy of BRMs in an appropriate retrovirus infected animal model. Efforts will be made to evaluate BRMs alone or in combination with other drugs in an appropriate animal/retrovirus model to determine their potential usefulness as a therapy for AIDS. BRMs are agents or methods used to alter the host's biological response to infection with a resultant therapeutic effect. BRMs may function in several ways. Some increase the host's antiviral responses by augmenting or restoring the effector arms directly or indirectly. Others may function to increase the growth and differentiation of lymphocytes or macrophages thus increasing the ability of the host to tolerate damage by cytotoxic drugs that may be used in the treatment of AIDS. Cytokines, lymphokines, monokines, growth factors, tumor necrosis factors and inducers of these proteins are examples of some of the BRMs known to date. The Division of Cancer Treatment (DCT) of the National Cancer Institute has ben developing these agents in the treatment of tumors. Until recently little work has been done to develop the use of BRMs alone or in combination with other drugs for the treatment of viral infections. It may be that therapies for AIDS which require long term treatment with an antiviral agent (e.g. nucleoside analogue) may require combination therapy with a modualtor of the immune response. BRMs could be used to decrease the toxicity of the drug by increasing the number of lymphocytes or aid in the immune response against this viral infection. At present, research into this area needs to be increased. It is the purpose of this solicitation to develop the use of BRMs for AIDS therapy. This will be accomplished by evaluation BRMs alone or in combination with other drugs in an retrovirusanimal model which mimics the disease AIDS.
本合同的目的是促进进入

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JULIE L. EISEMAN其他文献

JULIE L. EISEMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JULIE L. EISEMAN', 18)}}的其他基金

Preclinical Pharmacokinetic and Pharmacological Studies of Antitumor and other Th
抗肿瘤等药物的临床前药代动力学和药理学研究
  • 批准号:
    8655018
  • 财政年份:
    2011
  • 资助金额:
    $ 26.65万
  • 项目类别:
Preclinical Pharmacokinetic and Pharmacological Studies of Antitumor and other Th
抗肿瘤等药物的临床前药代动力学和药理学研究
  • 批准号:
    8342342
  • 财政年份:
    2011
  • 资助金额:
    $ 26.65万
  • 项目类别:
Pharmacokinetic and Pharmacological Studies of Antitumor and other Therapeutic Agents
抗肿瘤和其他治疗药物的药代动力学和药理学研究
  • 批准号:
    8844897
  • 财政年份:
    2011
  • 资助金额:
    $ 26.65万
  • 项目类别:
Preclinical Pharmacokinetic and Pharmacological Studies of Antitumor and other Th
抗肿瘤等药物的临床前药代动力学和药理学研究
  • 批准号:
    8429102
  • 财政年份:
    2011
  • 资助金额:
    $ 26.65万
  • 项目类别:
Pharmacokinetic and Pharmacological Studies of Antitumor and other Therapeutic Agents
抗肿瘤和其他治疗药物的药代动力学和药理学研究
  • 批准号:
    9035201
  • 财政年份:
    2011
  • 资助金额:
    $ 26.65万
  • 项目类别:
PRECLINICAL EVAL. OF TUBULIN BINDING AGENTS AND DUAL SPEC. PHOSP INHIB. IN RODENT
临床前评估。
  • 批准号:
    6928836
  • 财政年份:
    2005
  • 资助金额:
    $ 26.65万
  • 项目类别:
BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS
生物反应调节剂作为艾滋病疗法
  • 批准号:
    2296956
  • 财政年份:
    1987
  • 资助金额:
    $ 26.65万
  • 项目类别:
BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS
生物反应调节剂作为艾滋病疗法
  • 批准号:
    2296953
  • 财政年份:
    1987
  • 资助金额:
    $ 26.65万
  • 项目类别:
BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS
生物反应调节剂作为艾滋病疗法
  • 批准号:
    2296952
  • 财政年份:
    1987
  • 资助金额:
    $ 26.65万
  • 项目类别:
BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS
生物反应调节剂作为艾滋病疗法
  • 批准号:
    2296958
  • 财政年份:
    1987
  • 资助金额:
    $ 26.65万
  • 项目类别:

相似国自然基金

生长素响应因子(Auxin Response Factors)在拟南芥雄配子发育中的功能研究
  • 批准号:
    31970520
  • 批准年份:
    2019
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
新型GhDRP1(Drought Response Protein1) 调控棉花应答干旱的分子网络解析及育种利用评价
  • 批准号:
    31871668
  • 批准年份:
    2018
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
秀丽隐杆线虫ASI神经元off-response的环路与分子机制
  • 批准号:
    31600856
  • 批准年份:
    2016
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Germline Genetic Modifiers of Radiation Response
辐射反应的种系遗传修饰剂
  • 批准号:
    10741022
  • 财政年份:
    2023
  • 资助金额:
    $ 26.65万
  • 项目类别:
Investigating the impact of ethnicity on asthma: determining risk factors, modifiers, clinical phenotypes, and differential response to treatment.
调查种族对哮喘的影响:确定危险因素、调节因素、临床表型和对治疗的不同反应。
  • 批准号:
    nhmrc : 2005237
  • 财政年份:
    2021
  • 资助金额:
    $ 26.65万
  • 项目类别:
    Postgraduate Scholarships
Genetic modifiers of the Mediterranean-DASH diet Intervention for Neurodegenerative Delay (MIND) response
地中海 DASH 饮食的基因修饰 神经退行性延迟 (MIND) 反应干预
  • 批准号:
    10579433
  • 财政年份:
    2020
  • 资助金额:
    $ 26.65万
  • 项目类别:
Genetic modifiers of the Mediterranean-DASH diet Intervention for Neurodegenerative Delay (MIND) response
地中海 DASH 饮食的基因修饰 神经退行性延迟 (MIND) 反应干预
  • 批准号:
    10617272
  • 财政年份:
    2020
  • 资助金额:
    $ 26.65万
  • 项目类别:
Genetic modifiers of the Mediterranean-DASH diet Intervention for Neurodegenerative Delay (MIND) response
地中海 DASH 饮食的基因修饰 神经退行性延迟 (MIND) 反应干预
  • 批准号:
    10402905
  • 财政年份:
    2020
  • 资助金额:
    $ 26.65万
  • 项目类别:
Genetic modifiers of the Mediterranean-DASH diet Intervention for Neurodegenerative Delay (MIND) response
地中海 DASH 饮食的基因修饰 神经退行性延迟 (MIND) 反应干预
  • 批准号:
    10256753
  • 财政年份:
    2020
  • 资助金额:
    $ 26.65万
  • 项目类别:
Mutations in epigenetic modifiers and their impact on tumorigenesis and drug response in SCLC (B03+)
表观遗传修饰物的突变及其对 SCLC 肿瘤发生和药物反应的影响 (B03)
  • 批准号:
    426731068
  • 财政年份:
    2019
  • 资助金额:
    $ 26.65万
  • 项目类别:
    Collaborative Research Centres
Development of a Screening System Using Mouse-model for Chemical Modifiers of Radiation Response
使用小鼠模型开发辐射响应化学修饰剂筛选系统
  • 批准号:
    19K08130
  • 财政年份:
    2019
  • 资助金额:
    $ 26.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mutation analysis of somatic signalling modifiers of the DNA damage response in germ cells
生殖细胞 DNA 损伤反应体细胞信号修饰因子的突变分析
  • 批准号:
    418036758
  • 财政年份:
    2019
  • 资助金额:
    $ 26.65万
  • 项目类别:
    Research Grants
Effects of Immune response modifiers (IRMs) on the Immune system response toInjury in mice and on the developement of the two-hit response phenotype
免疫反应调节剂 (IRM) 对小鼠免疫系统损伤反应和二次攻击反应表型发展的影响
  • 批准号:
    241230198
  • 财政年份:
    2013
  • 资助金额:
    $ 26.65万
  • 项目类别:
    Research Fellowships
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了